Continuous Improvement Officer 2
Job description:
We are at the centre of the rapidly growing cell and gene therapy sector. We deliver life-changing therapies to patients, and so can you.
We are currently recruiting for a Continuous Improvement Officer to join the Analytical Development and QC team. The purpose of this role is to support continuous improvement (CI) activities, such as, identifying areas for improvement and implementing and managing improvement projects.
Our ADQC team supports the development of products through analytical testing to facilitate manufacturing and process development, ensuring appropriate quality controls and use of analytics.
Your responsibilities in this role would be:
- Participate in ongoing improvement projects in analytical department by supporting project lead in technical areas (e.g. development of databases, trackers, spreadsheets)
- Develop knowledge and skills in continuous improvement and project management areas
- Develop technical skills in areas such as database management, programming and Excel to support improvement initiatives
- Work alongside members of the department to identify improvements by participating in gap analysis meetings
- Creation and maintenance of Excel-based spreadsheets (standard trackers, calculation templates)
We are looking for:
- Educated to degree level within Life Sciences or Information Technology (IT)
- Proficient in the use of MS Office (Excel, Word, PowerPoint, Outlook)
- The ability to build relationships and cross collaborate
- Proven skills in critical thinking and troubleshooting
- Basic understanding of project management and/or continuous improvement concepts
- Knowledge of additional industry-specific software (i.e. LIMS, SQL, Python) is preferred
- Strong interest in technology – learning and utilizing new software, researching available technology, etc.
About Us:
We are a quality and innovation-led cell and gene therapy CDMO with a mission to enable our clients to deliver life changing therapies to patients around the world.
Our innovative solutions and proven expertise allow our clients in the biotech and biopharma industry, to deliver life-saving therapies to reach even more patients.
The success of cell and gene therapy products transforms outcomes for millions of people suffering from some of the world’s worst diseases and medical conditions.
What’s in it for you:
- Highly competitive reward packages
- Wellbeing programmes
- Development opportunities
- Welcoming, friendly, supportive colleagues
- A diverse and inclusive working environment
- Our values are: Responsible, Responsive, Resilient, Respect
- State of the art laboratory and manufacturing facilities
We work together, motivated to make a difference, and so can you.
We offer:
Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.
Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells.This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).
Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.